Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

8.200 +0.110 (+1.36%)
Streaming Delayed Price Updated: 3:11 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces 2024 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Outlook For Aurinia Pharmaceuticals
Via Benzinga
Aurinia Provides Update on Proxy Statement
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
AUPH stock results show that Aurinia Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
From Aurinia Pharmaceuticals Inc.
Via Business Wire
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated. 
Via Benzinga
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What's Going On With Aurinia Pharmaceuticals Stock?
Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To... 
Via Benzinga
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What's Going On With Aurinia Pharmaceuticals Stock?
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week. 
Via Benzinga
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.